Halberd Corp – Update July 13, 2020 – Addresses Certain Issues
Jackson Center, PA, July 13, 2020 – Halberd Corp. (OTC PINK: "HALB") today issued a statement to clarify certain items within its charter regarding allowable debt. There have been inaccurate rumors that have put the company in a negative light. One of these is that the company intends to take on convertible debt. Nothing could be further from the truth. Halberd’s corporate charter prohibits it from issuing any kind of convertible financial instrument, debt or ...
COVID-19 Cytokine Storm, Coronavirus’ Deadliest Stage – Halberd’s US Patent Pending Treatment Now Explained!
Jackson Center, PA, July 7, 2020 – Halberd Corp. (OTC PINK: "HALB") today explains the second of three (3) COVID -19 (Coronavirus) patent pending treatments - “Method for Treating Covid-19 Inflammatory Cytokine Storm for the Reduction of Morbidity and Mortality in Covid-19 Patients” - which was filed with the U.S. Patent and Trademark Office on April 8, 2020. Halberd Corporation holds the exclusive worldwide license to this technology To combat the patient’s overproduction of inflammatory ...
Halberd Establishes UK Subsidiary
Jackson Center, PA, July 1, 2020 – Halberd Corporation (OTC-PINK: "HALB") announced the establishment of a subsidiary in the United Kingdom to facilitate access to European research facilities and markets. The subsidiary is Halberd Corporation UK, Ltd. William A. Hartman, Chairman, President & CEO of Halberd, stated, “This is the first step in our overall plan to expand our reach beyond North America and to establish a global footprint which is necessary given the breadth ...
Halberd Method for Treating and Curing the COVID-19 Infection Explained
Jackson Center, PA, June 29, 2020 – Halberd Corporation (OTC-PINK: "HALB") today unveils the first of three (3) COVID -19 (Coronavirus) patent pending treatment methods -- the first titled, “Method for Treating and Curing Covid-19 Infection” -- filed with the U.S. Patent and Trademark Office on March 16, 2020. Halberd holds exclusive worldwide license to this technology. The method applicable to any disease entails the extracorporeal (outside the body) treatment of a patient’s blood or ...
NFL Retired Players Association’s Chief Medical Officer Joins Halberd Corporation to Lead COVID-19 Efforts
Effective Immediately! Jackson Center, PA, June 22, 2020 – Halberd Corporation (OTC Pink: HALB) announced the appointment of Dr. Patricio F. Reyes to the position of Chief Technical Officer effective immediately. He will report to Halberd’s new Chairman, President and CEO, William A. Hartman and is currently the Chief Medical Officer of the NFL’s Retired Players Association (NFL RPA). Dr. Reyes will head up Halberd Corporation’s efforts in the development of a treatment to eradicate ...
Halberd Designated “Pink Current Information” by OTC and Continues Technology Progress
Jackson Center, PA, June 15, 2020 –Halberd Corporation (OTC Pink: HALB) announced that OTC Markets has completed its background investigation and analysis of all filings by Halberd Corporation and now designates Halberd Corporation as "Pink Current Information". William A. Hartman, newly appointed Chairman, President and CEO explains, “Now that Halberd has been designated by OTC Markets as current in its filings and is now current with the Colorado Secretary of State, this completes the first ...